Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS)
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS)
Authors
Keywords
DPP4 inhibitors, Sitagliptin, Acute coronary syndrome, Diabetes mellitus
Journal
Cardiovascular Diabetology
Volume 12, Issue 1, Pages 53
Publisher
Springer Nature
Online
2013-03-28
DOI
10.1186/1475-2840-12-53
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
- (2013) Samuel S Engel et al. Cardiovascular Diabetology
- Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)
- (2012) Masaya Sakamoto et al. Cardiovascular Diabetology
- A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E–Deficient Mice
- (2012) Junichi Matsubara et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- DPP-4 inhibitors in the treatment of type 2 diabetes
- (2011) Hélène Duez et al. BIOCHEMICAL PHARMACOLOGY
- Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
- (2011) Zubair Shah et al. CIRCULATION
- Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial
- (2011) S. L. Ellis et al. DIABETIC MEDICINE
- Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome
- (2010) David S Tofovic et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1
- (2010) G. P. Fadini et al. DIABETES CARE
- Exendin-4 Protects Oxidative Stress-Induced β-Cell Apoptosis through Reduced JNK and GSK3β Activity
- (2010) Ju-Young Kim et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration
- (2010) Janet Woodcock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global estimates of the prevalence of diabetes for 2010 and 2030
- (2009) J.E. Shaw et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
- (2009) Roger Yazbeck et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Effects of Intravenous Glucagon-Like Peptide-1 on Glucose Control and Hemodynamics After Coronary Artery Bypass Surgery in Patients With Type 2 Diabetes
- (2008) Karsten Müssig et al. AMERICAN JOURNAL OF CARDIOLOGY
- Sitagliptin Augments Sympathetic Enhancement of the Renovascular Effects of Angiotensin II in Genetic Hypertension
- (2008) Edwin K. Jackson et al. HYPERTENSION
- Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension
- (2008) Goutam C. Mistry et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now